ENJAYMO

This brand name is authorized in Austria, Finland, France, Croatia, Ireland, Israel, Italy, Japan, Lithuania, United States

Active ingredients

The drug ENJAYMO contains one active pharmaceutical ingredient (API):

1 Sutimlimab UNII GNWE7KJ995 - SUTIMLIMAB

Sutimlimab is an IgG, subclass 4 (IgG4) monoclonal antibody (mAb) that inhibits the classical pathway (CP) and specifically binds to complement protein component 1, s subcomponent (C1s), a serine protease that cleaves C4. The activities of the lectin and alternative complement pathways are not inhibited by sutimlimab. Inhibition of the classical complement pathway at the level of C1s prevents deposition of complement opsonins on the surface of red blood cells, resulting in inhibition of haemolysis in patients with CAD. Read about Sutimlimab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ENJAYMO Solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AJ04		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AJ Complement inhibitors
Discover more medicines within L04AJ04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 033391
Country: FR	Base de données publique des médicaments	Identifier(s): 69505243
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9207
Country: IT	Agenzia del Farmaco	Identifier(s): 050307014, 050307026
Country: JP	医薬品医療機器総合機構	Identifier(s): 6399431A1023
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095972, 1095973
Country: US	FDA, National Drug Code	Identifier(s): 80203-347